Quantifying Endothelial Progenitor Cells for Health Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a standardized approach to assess the proliferative potential of endothelial progenitor cells (EPCs) and endothelial cells, which is crucial for understanding endothelial health and predicting health status, as existing assays rely heavily on cell surface markers that can vary with physiological state and do not quantify intrinsic proliferative capacity.
Innovation Solution
Quantifying levels of circulating endothelial progenitor cells and correlating them with inflammatory and regenerative markers in the blood, using specific markers such as CD133, CD34, VEGF-receptor, and others, to predict health status and endothelial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cell surface markers (CD34, CD133, VEGF-receptor) are used to identify and quantify endothelial progenitor cells, then the assessment of endothelial health can be performed, but the measurement accuracy is reduced because cell surface marker expression varies with physiological state and does not reflect intrinsic proliferative capacity
Solution Approach 1:
The patent transitions from using cell surface marker expression levels (which vary with physiological state) to measuring intrinsic proliferative capacity through colony-forming unit assays and flow cytometry-based proliferation assays. This parameter change from static marker expression to dynamic functional measurement resolves the contradiction by providing accurate assessment of endothelial health while maintaining operational feasibility through standardized in vitro assays.
2Loss of information
If a hierarchy of stem and progenitor cells analogous to hematopoietic cell system is established for endothelial cells, then the understanding of endothelial cell development improves, but the device complexity increases due to need for multiple assays and markers
Solution Approach 1:
The patent segments the endothelial progenitor cell population into hierarchical levels (endothelial colony-forming units, endothelial progenitor cells, and mature endothelial cells) based on proliferative potential. This segmentation allows comprehensive understanding of endothelial cell development while managing complexity through defined hierarchical categories that can be assessed using a panel of standardized assays rather than exhaustive individual cell analysis.
Solution Approach 2:
The patent employs flow cytometry as a universal platform that can simultaneously measure multiple parameters (cell surface markers, proliferation markers, apoptosis markers) across different endothelial cell populations. This multi-functional approach consolidates multiple assessment methods into a single instrument, reducing overall system complexity while maintaining comprehensive analytical capability.
Data Source
AI summary
Disclosed are means, methods, and protocols for identifying and quantifying circulating regenerative and/or endothelial cells in a mammal in order to predict health status and risk of various pathologies. In one embodiment, determination of cardiovascular risk is performed using a blood test that assesses circulation of CD133 expressing cells, together with OCT-4 expressing cells, together with CD34/CD205 expressing cells.